Isabelle Mohr

Isabelle Mohr

Auto-generated profile, based on publicly available information

Isabelle Mohr

Internal Medicine IV, Department of Gastroenterology University Hospital Heidelberg Heidelberg Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
IMIsabelle Mohr
Isabelle Mohr
JPJan Pfeiffenberger
Jan Pfeiffenberger
EEEcem Eker
Ecem Eker
UMUta Merle
Uta Merle
APAurélia Poujois
Aurélia Poujois
KWKarl Heinz Weiss
Karl Heinz Weiss

1 October 2020 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
CFCora Freund
Cora Freund
AWArne Wahlers
Arne Wahlers
NBNima Haji Begli
Nima Haji Begli
YLYvonne Leopold
Yvonne Leopold
PKPetra Klöters-Plachky
Petra Klöters-Plachky
KWKarl Heinz Weiss
Karl Heinz Weiss

12 November 2022 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
IMIsabelle Mohr
Isabelle Mohr
HBHélène Bourhis
Hélène Bourhis
FWFrance Woimant
France Woimant
MOMickael Alexandre Obadia
Mickael Alexandre Obadia
MMMüzeyyen Morgil
Müzeyyen Morgil
KWKarl Heinz Weiss
Karl Heinz Weiss

21 January 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
IMIsabelle Mohr
Isabelle Mohr
PLPatrick Lamade
Patrick Lamade
CWChristophe Weber
Christophe Weber
VLViola Leidner
Viola Leidner
SKSebastian Köhrer
Sebastian Köhrer
UMUta Merle
Uta Merle
Background & Aim: Twenty-four-hour urinary copper excretion (24 h-UCE) is the standard diagnostic tool for dose adjustments in maintenance therapy in Wilson disease (WD) patients. Guidelines lack data if both variants of 24 h-UCE measurement (with or without 48 h of treatment interruption) are equally interpretable. Methods: Eighty-four patients with a confirmed diagnosis of WD treated with chelators (50% of patients with D-Penicillamine and 50% with trientine) and with pairwise 24-h-UCE values on-therapy and off-therapy were included in the analysis. Pairwise urinary sampling between October 2022 (T0) and a 12-month FU (T2) was compared, and exchangeable copper (CuEXC) was additionally measured at T0. Results: Among the 84 patients, 65% had predominant hepatic symptoms, the median age was 42 years, and 58% were female. At T0, patients were in the stable maintenance phase, with a median treatment duration of 21.9 years. The levels of the biochemical markers liver and copper metabolism remained stable over the 12-month observation period for all patients. 24 h-UCE off-therapy significantly decreased from T0 to T2 (p = 0.03), whereas no statistically significant differences were detected for 24 h-UCE after therapy. Both sampling methods did not correlate. CuEXC was significantly correlated with 24 h-UCE after 48 h of dose interruption (p = 0.018) but not with 24 h-UCE after therapy. A total of 46% of the 24 h-UCE value pairs were discordant, laying out the aimed therapeutic ranges given in current international guidelines. Conclusion: Off-therapy 24 h-UCE reflects the “free” copper pool more accurately than does urinary sampling. The study shows discordant results for both sampling methods in approximately half of the patients, revealing that interpretation of 24 h-UCE with respect to chelator-dosing decisions should be performed with caution.

17 September 2024 in JIMD Reports
Verified
Journal Article
Open access
IMIsabelle Mohr
Isabelle Mohr
TSTimo Schmitt
Timo Schmitt
CWChristophe Weber
Christophe Weber
NSNicolas Schall
Nicolas Schall
VLViola Yuriko Leidner
Viola Yuriko Leidner
UMUta Merle
Uta Merle
This study evaluates the effectiveness and safety of trientine dihydrochloride (TETA 2‐HCl) in patients with Wilson disease (WD) following a switch from trientine tetrahydrochloride (TETA 4‐HCl). A total of 30 WD patients with stable copper metabolism were identified for treatment with TETA 2‐HCl (Cufence™) after prior use of TETA 4‐HCl (Cuprior™). Biochemical markers including urinary copper, non‐ceruloplasmin bound copper (NCC) and liver function were analyzed at baseline and followed up over 12 months. Safety was assessed based on reported adverse events (AEs). Urinary copper levels and NCC remained stable across all follow‐ups, indicating adequate copper metabolism control. Reported AEs during TETA 2‐HCl treatment were mostly gastrointestinal discomfort (n = 6). In two patients, progressive elevation of transaminases occurred (despite stable copper metabolism). AEs led to discontinuation of treatment in five cases. Median baseline dose per day was 10.2 mg TETA 4‐HCl/kg bodyweight, whereas median baseline dose after therapeutic switch to TETA 2‐HCl was 12.8 mg/kg bodyweight. Median daily dose at 12 months did not differ significantly from TETA 2‐HCl dose at switching timepoint, with stable biochemical markers and markers of copper metabolism in most (25/30) of the patients. Transitioning from TETA 4‐HCl to TETA 2‐HCl maintained stable copper parameters and liver function in most of analyzed patients. TETA 2‐HCl treatment was generally well tolerated, suggesting that switching medications is safe and effective. In our real‐life cohort, adjustment factor of ~1.25× for the switch of TETA 4‐HCl to TETA 2‐HCl resulted in adequate copper metabolism control.

1 January 2025 in Case Reports in Hepatology
Verified
Journal Article
Open access
TRThomas Rösner
Thomas Rösner
JGJulia Grenz
Julia Grenz
MSMarlene Schaumäker
Marlene Schaumäker
SCSven Cuntz
Sven Cuntz
NBNorbert Blank
Norbert Blank
IMIsabelle Mohr
Isabelle Mohr
Herpes simplex virus (HSV) infections are common in the European population, typically presenting with mucocutaneous and anogenital manifestations. However, disseminated infections and organ involvement are rare, usually occurring in immunocompromised individuals, particularly after hematopoietic stem cell or solid organ transplantation. HSV1/2‐induced hepatitis is infrequent but can result in acute liver failure (ALF) and increased mortality. We present a case of fulminant ALF caused by disseminated primary HSV2 infection in a fifty‐year‐old male with rheumatoid arthritis treated with the JAK‐inhibitor upadacitinib for 3 months prior to presentation. Clinical examination revealed severe oropharyngeal mucositis and hepatic encephalopathy. Initial laboratory results showed bicytopenia, significantly elevated transaminases, bilirubin, inflammatory markers, and severe coagulopathy. Empirical treatment with an antimicrobial regimen, intravenous aciclovir, acetylcysteine, and plasmapheresis (PPH) was initiated. The patient was listed for urgent liver transplantation based on King’s College criteria. Further investigations revealed a high viral load of HSV2 DNA in the blood, and transjugular liver biopsy confirmed extensive liver necrosis with positive HSV staining. Despite antiviral therapy, the HSV2 viral load remained high, indicating resistance, and the patient was deemed “nontransplantable” due to clinical deterioration with progressive hepatic coma, hemorrhagic–septic shock, multiorgan failure, and secondary bowel ischemia, ultimately leading to the patient’s death from refractory shock. This is only the second documented case of fulminant ALF due to HSV2 hepatitis in a patient undergoing JAK inhibition, and the first involving upadacitinib. It highlights the importance of considering primary herpesvirus infection as a potential cause of ALF, particularly in immunocompromised patients, and underscores the need for early antiviral intervention to improve outcomes.